Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECT-HN
2025-520735-16-00Phase 2Completed
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Jan 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of peplomycin, cetuximab, carboplatin, cisplatin, fluorouracil and 1 more in Oral Mucosal Carcinoma, oropharyngeal squamous cell carcinoma (OPSCC) and head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: Objective response rate superiority of electrochemotherapy. Started Jan 2025; status: completed.
02
Drugs
peplomycincetuximabcarboplatincisplatinfluorouracil
03
Conditions
Oral Mucosal Carcinomaoropharyngeal squamous cell carcinoma (OPSCC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2025-520735-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520735-16-00.